Martin Jacqueline, Curtain Colin M, Salahudeen Mohammed S, Janson Sonja, Kodgire Sachin, Tsai Danny
School of Pharmacy and Pharmacology, University of Tasmania, Sandy Bay, Australia; Pharmacy Department, Alice Springs Hospital, Alice Springs, Australia.
School of Pharmacy and Pharmacology, University of Tasmania, Sandy Bay, Australia.
Clin Ther. 2025 Apr;47(4):e1-e7. doi: 10.1016/j.clinthera.2025.01.001. Epub 2025 Jan 27.
To determine the incidence of therapeutic target attainment using a three-times per week protocol for vancomycin therapy given during the last hour of intermittent hemodialysis (HD).
A single-center retrospective cohort study was conducted of patient medical records in a remote dialysis center from January 2017 to July 2023. Adult patients with chronic kidney disease stage 5 on ≥3 months of intermittent HD who had received a course of vancomycin therapy with ≥1 serum vancomycin concentration recorded were included. Demographic and dosing data were collected. Clinician adherence with the dosing protocol and attainment of the therapeutic target (trough concentration within 15-20 mg/L) following the loading and maintenance doses were assessed. Factors associated with target nonattainment following the loading dose were analyzed, and the 48- and 72-h maintenance dosing intervals were analyzed for target nonattainment.
A total of 98 vancomycin courses (67 patients) were available for analysis. Only 38% of the loading doses were prescribed as per protocol. Following the loading dose, 25% of trough concentrations achieved the therapeutic target concentration (15-20 mg/L), 25% returned a supra-therapeutic concentration (>20 mg/L) and 50% were sub-therapeutic (<15 mg/L). When compared with those achieving target, sub-therapeutic concentrations were associated with a lower loading dose (median 16.6 vs 20.0 mg/kg, P < 0.002), and supra-therapeutic concentrations had a shorter dosing interval between the loading dose and first maintenance dose (median 31.5 vs 39.0 h, P = 0.06). Of the 201 maintenance trough concentrations collected, 65% were therapeutic, 21% were sub-therapeutic and 14% were supra-therapeutic, with an overall median trough concentration of 17.3 mg/L. As the treatment duration increased, an increase was seen in the number of dose adjustments required to achieve the target trough concentration. The 48-h dosing interval was associated with more supra-therapeutic concentrations and the 72-h interval was associated with more sub-therapeutic concentrations (df = 2, P = 0.022).
We have identified a high rate of target nonattainment for HD patients on a three times a week vancomycin dosing regimen. We recommend a loading dose of 20 to 25 mg/kg irrespective of the indication and a better-defined dosing interval after the loading dose. A higher maintenance dose should be prescribed when the time to next dialysis session is 72 h. Further pharmacokinetic studies are needed to assess factors influencing target concentration attainment following the maintenance doses and to determine an optimal dosing regimen.
确定在间歇性血液透析(HD)的最后一小时给予万古霉素治疗,采用每周三次方案时治疗目标达成率。
对2017年1月至2023年7月间一家偏远透析中心的患者病历进行单中心回顾性队列研究。纳入接受过万古霉素治疗疗程且记录有≥1次血清万古霉素浓度的慢性肾脏病5期成年患者,这些患者进行间歇性HD≥3个月。收集人口统计学和给药数据。评估临床医生对给药方案的依从性以及负荷剂量和维持剂量后治疗目标(谷浓度在15 - 20mg/L之间)的达成情况。分析负荷剂量后未达成目标的相关因素,并分析48小时和72小时维持给药间隔未达成目标的情况。
共有98个万古霉素疗程(67例患者)可供分析。只有38%的负荷剂量按方案规定开具。负荷剂量后,25%的谷浓度达到治疗目标浓度(15 - 20mg/L),25%的谷浓度高于治疗浓度(>20mg/L),50%的谷浓度低于治疗浓度(<15mg/L)。与达成目标的患者相比,低于治疗浓度与较低的负荷剂量相关(中位数16.6 vs 20.0mg/kg,P < 0.002),高于治疗浓度在负荷剂量和首次维持剂量之间的给药间隔较短(中位数31.5 vs 39.0小时,P = 0.06)。在收集的201个维持谷浓度中,65%为治疗性,21%为低于治疗性,14%为高于治疗性,总体谷浓度中位数为17.3mg/L。随着治疗时间延长,为达到目标谷浓度所需的剂量调整次数增加。48小时给药间隔与更多高于治疗浓度相关,72小时间隔与更多低于治疗浓度相关(自由度 = 2,P = 0.022)。
我们发现接受每周三次万古霉素给药方案的HD患者目标未达成率很高。我们建议无论适应证如何,负荷剂量为20至25mg/kg,并在负荷剂量后确定更明确的给药间隔。当下一次透析时间为72小时时,应开具更高的维持剂量。需要进一步的药代动力学研究来评估影响维持剂量后目标浓度达成的因素,并确定最佳给药方案。